Agios Pharmaceuticals' Anemia ID offers no-cost genetic testing to patients in the United States with suspected hereditary anemias. The program is offered in partnership with PerkinElmer Genomics.
The program "provides a diagnosis confirming the underlying cause(s) of a patient’s hereditary anemia, supports the development of an effective management plan, informs genetic counseling discussions, and enables the identification of appropriate treatment options or clinical trials."
Read more about Anemia ID by visiting its website.
Posted 9/27/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
